Genprex, Inc.

132 articles with Genprex, Inc.

• Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies

  3/23/2023

  Rodney Varner , CEO of Genprex, Inc. today commended The U.S. Food and Drug Administration's (FDA) initiative that aims to expedite the development of gene therapies for patients with rare diseases.

• Genprex to Present at Bioprocessing Summit Conference

  3/13/2023

  Genprex, Inc. today announced the Company's Chief Manufacturing and Technology Officer, Hemant Kumar, Ph.D., will participate in the upcoming Bioprocessing Summit Europe Conference taking place March 14-16, 2023 in Barcelona, Spain.

• 

  CRISPR/ViaCyte and Genprex Vie for First Diabetes Gene Therapy

  3/13/2023

  Partners CRISPR and ViaCyte (Vertex), and Genprex are pioneers in the quest to develop a gene therapy for Type 1 diabetes.

• Genprex to Participate in March Investor and Industry Conferences

  3/8/2023

  Genprex, Inc. today announced the Company's participation in the following upcoming investor and industry conferences to be held in March 2023.

• Genprex, Inc. Announces $4 Million Registered Direct Offering With a Single, Healthcare-Focused Institutional Investor

  2/27/2023

  Genprex, Inc. announced it has entered into a securities purchase agreement with a single, healthcare-focused institutional investor for the purchase and sale of 3,809,524 shares of its common stock together with warrants to purchase up to 3,809,524 shares of common stock at a combined purchase price of $1.05 per share and accompanying warrant, pursuant to a registered direct offering.

• Genprex Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Gene Therapy to Treat Type 1 Diabetes

  2/23/2023

  Genprex, today announced that data highlighting the potential of Genprex's gene therapy for Type 1 diabetes is being presented by its research collaborators at the University of Pittsburgh (Pitt) at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) taking place February 22-25, 2023 in Berlin, Germany. 

• Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

  1/5/2023

  Genprex, Inc. announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors.

• Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes

  1/4/2023

  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX) today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.

• Genprex Strengthens Diabetes Gene Therapy Program with License of Additional Technology from University of Pittsburgh

  12/15/2022

  Genprex, Inc. today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene therapy.

• Genprex Receives Safety Review Committee Approval to Proceed to Final Cohort in Acclaim-1 Phase 1 Dose Escalation Trial of REQORSA® in Combination with Tagrisso® in Advanced Non-Small Cell Lung Cancer

  12/14/2022

  Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX) today announced that the Safety Review Committee (SRC) has approved continuation to the third and final cohort in the dose escalation Phase 1 portion of the Acclaim-1 Phase 1/2 clinical trial of REQORSA® in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC).

• Genprex to Present at Upcoming December Investor Conference

  12/2/2022

  Genprex, Inc. today announced that its Executive Vice President will be providing an overview of the Company's gene therapies for cancer and diabetes at the following investor conference in December 2022.

• Genprex to Present at Upcoming October Investor and Industry Conferences

  10/7/2022

  Genprex, Inc. today announced the Company's participation in the following upcoming investor and industry conferences to be held in October 2022.

• Genprex to Present at Upcoming September 2022 Investor Conference

  9/8/2022

  Genprex, Inc. announced that its Chief Financial Officer, Ryan Confer, will be providing a virtual overview of the Company's gene therapies for cancer and diabetes at the following investor conference in September 2022.

• Genprex Announces U.S. Patent for REQORSA™ Immunogene Therapy in Combination with Immune Checkpoint Inhibitors to Treat Cancers

  8/16/2022

  Genprex, Inc. today announced that the United States Patent and Trademark Office (USPTO) has granted Genprex U.S. Patent No: 11,278,592 B2.

• Genprex Announces Safety Review Committee Approves Dose Escalation in Acclaim-1 Phase 1/2 Trial of REQORSA™ in Combination with Tagrisso® in Non-Small Cell Lung Cancer

  8/15/2022

  Genprex, Inc. today announced that the Safety Review Committee (SRC) has approved continuation of the Acclaim-1 Phase 1/2 clinical trial of REQORSA™ in combination with Tagrisso® (osimertinib) to treat late-stage non-small cell lung cancer (NSCLC) following a review of the first cohort of patients in the Phase 1 portion of the trial.

• Genprex to Participate in Next Generation Lipid-Based Nanoparticles Delivery Summit

  7/13/2022

  Genprex, Inc. today announced that Company manufacturing leadership will present sessions on cutting edge topics in lipid-based nanoparticle delivery systems at the upcoming Next Generation Lipid-Based Nanoparticles Delivery Summit taking place from July 19-21, 2022 in Boston.    

• Genprex to Present at Upcoming June Investor Conferences

  6/2/2022

  Genprex, Inc. today announced the Company's participation in the following upcoming investor and industry conferences to be held in June 2022.

• Genprex to Present at Upcoming Investor Conference in May 2022

  5/19/2022

  Corporate Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes.

• Genprex's Chief Medical Officer to Be Featured as an Expert Panelist at the 33rd Annual Cancer Progress Conference

  5/9/2022

  Genprex, Inc. today announced that its Chief Medical Officer, Mark Berger, M.D., will be featured as an expert panelist at the 33rd Annual Cancer Progress Conference, taking place virtually May 10-12, 2022.

• Genprex Issues Shareholder Letter and Provides 2022 Corporate Update

  5/5/2022

  Genprex, Inc. announced that it has issued a shareholder letter and corporate update outlining the Company's recent progress in its clinical development programs and key milestones and achievements for 2022 and beyond.